Accueil   Diary - News   All news Alizé Pharma will present clinical results

Alizé Pharma will present clinical results

Alizé Pharma presents clinical results from the AZP-531 program at the American Diabetes Association 75th Scientific Sessions

Final data will be revealed from Phase Ia trial in healthy volunteers and Phase Ib trial in overweight/obese subjects

 

Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, will present the results from two Phase I clinical trials with its unacylated ghrelin analog AZP-531 during the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston on June 5-9,2015.

 

 Read the press release

 

ALIZE  NEWSLETTER